communityacquir
pneumoniaback
basic
marc
j
bonten
jan
jelrik
oosterheert
background
lower
respiratori
tract
infect
among
common
infecti
diseas
worldwid
caus
inflamm
consolid
lung
tissu
due
infecti
agent
clinic
criteria
diagnosi
includ
chest
pain
cough
auscultatori
find
rale
evid
pulmonari
consolid
fever
leukocytosi
radiograph
evid
presenc
new
infiltr
chest
radiograph
laboratori
evid
support
diagnosi
elderli
patient
underli
condit
cerebroand
cardiovascular
diseas
chronic
obstruct
pulmonari
diseas
copd
alcohol
increas
risk
develop
lower
respiratori
tract
infect
complic
cours
infect
complic
includ
develop
progress
pneumonia
pleural
empyema
uncontrol
sepsi
death
sometim
even
despit
appropri
antimicrobi
treatment
differ
pathogenesi
caus
microorgan
healthcareassoci
communityacquir
pneumonia
cap
usual
distinguish
cap
repres
broad
spectrum
diseas
sever
rang
mild
pneumonia
manag
gener
practition
sever
pneumonia
septic
shock
need
treatment
intens
care
unit
icu
case
cap
success
manag
primari
care
approxim
patient
need
hospit
treatment
icu
respect
despit
widespread
avail
antibiot
reduc
mortal
sinc
introduct
lower
respiratori
tract
infect
remain
import
infecti
caus
death
develop
world
instanc
absolut
mortal
due
pneumonia
increas
past
year
netherland
unit
state
estim
annual
cost
treat
cap
excess
billion
us
unit
kingdom
billion
us
unit
state
lower
respiratori
tract
infect
frequent
caus
bacteria
virus
treatment
direct
toward
caus
organ
antibiot
prescrib
bacteri
infect
withheld
nonbacteri
caus
inflamm
yet
caus
agent
usual
identifi
time
treatment
must
initi
empir
therapi
therefor
cover
like
pathogen
impli
unavoid
empir
therapi
frequent
includ
wider
rang
pathogen
thu
broader
antibiot
spectrum
choic
exclus
cover
pathogen
involv
popul
level
quantiti
antibiot
prescrib
linearli
relat
antibiot
resist
unnecessari
antibiot
use
therefor
prevent
despit
paradigm
overus
antibiot
frequent
occur
especi
case
viral
infect
yet
goal
minim
unnecessari
antibiot
use
must
balanc
constantli
urg
cover
potenti
pathogen
order
prescrib
optim
treatment
individu
patient
therefor
optim
therapeut
efficaci
empir
treatment
prevent
unnecessari
antibiot
use
becom
import
issu
manag
lower
respiratori
tract
infect
chapter
etiolog
diagnost
therapeut
prevent
consider
describ
optim
antibiot
prescript
individu
patient
lower
respiratori
tract
infect
keep
antibiot
resist
develop
popul
level
mind
worldwid
streptococcu
pneumonia
far
import
pathogen
cap
frequent
isol
bacteria
haemophilu
influenza
staphylococcu
aureu
incid
atyp
pathogen
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
pneumophila
gener
lower
aforement
bacteria
although
variat
may
larg
pseudomona
aeruginosa
relev
patient
structur
lung
damag
bronchiectasi
copd
frequent
viral
caus
cap
includ
influenza
viru
parainfluenza
viru
viral
pneumonia
due
infect
influenza
respiratori
syncyti
viru
coronavirus
parainfluenza
viru
even
rhinovirus
life
threaten
elderli
immunocompromis
patient
influenza
pneumonia
may
complic
secondari
bacteri
infect
caus
aureu
pneumonia
h
influenza
gramneg
pathogen
recent
coronavirus
recogn
caus
sever
lower
respiratori
tract
infect
sar
coronaviru
caus
sever
cap
associ
high
mortal
rate
even
previous
healthi
adult
nonsar
coronavirus
coronaviru
associ
lower
respiratori
tract
infect
children
adult
human
metapneumoviru
increasingli
recogn
caus
respiratori
failur
children
pneumonia
elderli
importantli
episod
cap
remain
unknown
etiolog
rapid
reliabl
diagnost
result
need
prudent
pathogentailor
antibiot
strategi
current
avail
method
etiolog
diagnosi
includ
clinic
radiolog
laboratori
find
gram
stain
sputum
urinari
antigen
test
specif
dna
detect
use
realtim
polymeras
chain
reaction
pcr
although
clinic
featur
associ
specif
caus
microorganismssuch
high
fever
acut
onset
diseas
chill
product
cough
thorac
pain
pneumonia
preced
influenza
aureusther
consensu
case
microbi
caus
cap
predict
use
clinic
radiograph
featur
new
opportun
includ
use
system
level
creactiv
protein
crp
procalcitonin
pct
yet
although
rais
crp
pct
level
claim
indic
bacteri
infect
crp
level
could
differenti
bacteri
viral
respiratori
tract
infect
adult
could
pct
children
admit
cap
anoth
perspect
though
pct
use
reduc
unnecessari
antibiot
prescript
patient
clinic
symptom
lrti
without
subsequ
advers
effect
patient
outcom
note
reduct
antibiot
use
primarili
achiev
withhold
antimicrobi
therapi
patient
acut
bronchiti
patient
cap
studi
routin
diagnost
procedur
identifi
caus
microorgan
includ
microbiolog
cultur
blood
sputum
serolog
test
acut
reconvalesc
blood
sampl
howev
clinic
valu
convent
diagnost
method
guid
treatment
cap
limit
low
sensit
consider
delay
cultur
sampl
invas
procedur
need
pleural
bronchoalveolar
fluid
might
increas
diagnost
yield
inher
suffer
diagnost
delay
one
studi
fiberopt
bronchoscopi
provid
etiolog
diagnosi
patient
convent
diagnost
method
fail
identifi
caus
microorgan
yet
pathogendirect
empir
therapi
studi
associ
better
clinic
outcom
patient
fiberopt
bronchoscopi
therefor
consid
case
treatment
failur
without
identifi
caus
microorgan
convent
diagnost
importantli
even
studi
set
extens
diagnost
test
approxim
episod
cap
remain
unknown
etiolog
use
sputum
gram
stain
diagnost
workup
cap
controversi
use
recommend
infecti
diseas
societi
america
idsa
american
thorac
societi
at
advantag
sputum
gram
stain
includ
wide
avail
low
cost
howev
adequ
sputum
sampl
alway
obtain
either
sputum
product
sampl
adequ
evalu
furthermor
sensit
specif
unknown
bacteria
identifi
uniform
definit
posit
stain
exist
urinari
antigen
test
two
urinari
antigen
test
avail
diagnos
microbi
caus
cap
pneumonia
urinari
antigen
test
binax
inc
portland
main
detect
within
minut
c
polysaccharid
wall
antigen
common
pneumonia
strain
one
studi
report
specif
sensit
yet
specif
might
reduc
due
nasopharyng
carriag
pneumococci
urinari
antigen
test
detect
l
pneumophila
type
test
accuraci
increas
sever
diseas
sensit
vari
approxim
mild
sever
cap
immedi
within
hour
hospit
admiss
therapi
legionnair
diseas
detect
test
increas
icufre
surviv
compar
therapi
initi
hour
anoth
approach
identifi
virus
atyp
bacteri
pathogen
respiratori
sampl
molecular
techniqu
polymeras
chain
reaction
pcr
novel
realtim
taqman
pcr
techniqu
sensit
specif
abl
detect
respiratori
virus
clinic
specimen
within
hour
yet
random
trial
addit
realtim
pcr
analysi
respiratori
virus
atyp
pathogen
nose
throat
swab
routin
diagnost
workup
improv
diagnost
yield
fail
reduc
antibiot
use
healthcareassoci
cost
among
patient
admit
lower
respiratori
tract
infect
cap
therapi
detail
descript
underli
mechan
antibiot
resist
beyond
scope
chapter
brief
alter
bacteri
protein
bind
penicillin
decreas
bind
affin
antimicrobi
suscept
penicillin
pneumonia
strain
also
like
resist
antibiot
macrolid
tetracyclin
fluoroquinolon
treatment
pneumococc
pneumonia
antibiot
concentr
exceed
mic
least
time
strain
reduc
suscept
penicillin
anticip
achiev
higher
dosag
penicillin
eg
million
unit
q
hour
amoxicillin
eg
gram
q
hour
clinic
studi
mortal
rate
patient
bacterem
pneumococc
pneumonia
treat
antibiot
compar
episod
caus
pneumococci
suscept
nonsuscept
penicillin
macrolid
resist
either
due
modif
target
site
encod
ermb
gene
activ
efflux
pump
remov
macrolid
cell
encod
mef
gene
pneumonia
erm
gene
associ
high
level
resist
macrolid
erythromycin
resist
base
efflux
mechan
overcom
use
newer
macrolid
azithromycin
newer
fluoroquinolon
levofloxacin
moxifloxacin
activ
vitro
relev
signific
aerob
gramposit
cocci
enterobacteriacea
h
influenza
catarrhali
legionella
speci
pneumonia
c
pneumonia
make
attract
compound
treatment
cap
develop
resist
fluoroquinolon
occur
even
treatment
howev
matter
seriou
concern
resist
fluoroquinolon
result
mutat
target
enzym
dna
gyras
topoisomeras
iv
therebi
reduc
inhibitori
effect
fluoroquinolon
bacteri
dna
synthesi
strain
usual
becom
fulli
resist
target
gene
mutat
resist
mechan
includ
alter
bacteri
cell
membran
activ
efflux
drug
importantli
preval
antibiot
resist
vari
geograph
instanc
preval
reduc
suscept
penicillin
among
pneumonia
around
spain
netherland
http
wwwearssrivmnl
furthermor
macrolid
resist
europ
caus
mutat
ermb
gene
wherea
presenc
efflux
pump
predomin
resist
mechan
pneumonia
macrolid
unit
state
therefor
decis
empir
antimicrobi
treatment
base
local
antibiot
resist
rate
recent
emerg
infect
mostli
skin
infect
sporad
sever
cap
caus
socal
communityassoci
methicillinresist
aureu
camrsa
report
unit
state
europ
camrsa
resist
antibiot
frequent
still
suscept
clindamycin
cotrimoxazol
fluoroquinolon
organ
known
recommend
treatment
aim
isol
pathogen
tabl
howev
initi
treatment
cap
recommend
recent
guidelin
predominantli
base
clinic
sever
present
rather
presum
caus
pathogen
tabl
predict
clinic
sever
sever
risk
classif
exist
includ
combin
underli
ill
age
clinic
featur
clinic
practic
broadspectrum
antibiot
prescrib
liber
patient
sever
cap
scap
therefor
reliabl
prognost
model
might
use
tailor
empir
therapi
individu
patient
pragmat
scap
could
defin
need
icu
admiss
howev
definit
includ
object
measur
depend
local
polici
icu
admiss
may
vari
consider
center
at
propos
defin
scap
presenc
certain
set
minor
major
clinic
sign
symptom
british
thorac
societi
defin
scap
use
less
similar
set
core
addit
preexist
advers
prognost
featur
anoth
algorithm
predict
mortal
risk
thu
sever
cap
pneumonia
sever
index
psi
classifi
patient
five
group
develop
score
system
mortal
rate
gradual
increas
per
class
class
class
vthe
at
criteria
high
sensit
low
specif
predict
icu
admiss
anoth
studi
patient
risk
class
v
psi
system
admit
icu
extent
criteria
algorithm
use
choos
empir
therapi
remain
determin
view
clinic
judgment
difficult
describ
object
term
remain
import
manag
patient
cap
result
nonexperiment
studi
suggest
initi
manag
patient
hospit
cap
requir
icu
admiss
combin
therapi
consist
antibiot
plu
macrolid
monotherapi
one
newer
fluoroquinolon
reduc
mortal
length
hospit
natur
strategi
would
increas
use
macrolid
fluoroquinolon
thu
select
antibiot
pressur
resist
benefici
valu
macrolid
fluoroquinolon
might
result
larger
previous
assum
role
atyp
pathogen
etiolog
cap
antiinflammatori
effect
macrolid
resist
import
pathogen
howev
nonexperiment
almost
case
retrospect
design
studi
may
result
confound
indic
till
random
control
trial
confirm
outcom
differ
newer
fluoroquinolon
levofloxacin
moxifloxacin
compar
antibiot
coamoxiclav
ceftriaxon
without
macrolid
three
random
trial
clinic
bacteriolog
success
fluoroquinolon
treatment
appear
better
two
studi
statist
signific
differ
fever
resolut
durat
hospit
favor
fluoroquinolon
treat
patient
also
observ
two
studi
yet
absolut
differ
rather
small
day
fever
resolut
hospit
signific
surviv
benefit
found
result
might
influenc
protocol
least
one
studi
switch
oral
treatment
patient
receiv
ceftriaxon
allow
day
adult
nonsever
cap
treatment
failur
compar
empir
regimen
atyp
coverag
compar
antibiot
metaanalysi
similar
conclus
reach
anoth
metaanalysi
trial
evalu
patient
treat
cap
trend
toward
increas
clinic
success
better
bacteriolog
erad
found
patient
receiv
atyp
coverag
especi
infect
legionella
pneumophila
yet
trend
disappear
highqual
studi
evalu
therefor
recommend
use
empir
treatment
either
combin
monotherapi
new
fluoroquinolon
patient
hospit
cap
base
studi
provid
level
iii
evid
recommend
length
antimicrobi
treatment
cap
usual
base
caus
pathogen
respons
treatment
presenc
comorbid
ill
complic
current
guidelin
recommend
treat
cap
caus
pneumonia
patient
afebril
hour
wherea
episod
caus
bacteria
associ
pulmonari
necrosi
eg
aureu
p
aeruginosa
klebsiella
anaerob
treat
week
durat
week
also
recommend
cap
caus
pneumonia
c
pneumonia
legionnair
diseas
immunocompet
individu
treatment
length
could
reduc
use
azithromycin
due
long
halflif
tissu
although
longer
cours
probabl
need
legionella
infect
recommend
treatment
durat
base
result
control
trial
recent
treatment
durat
day
amoxicillin
clavulan
acid
compar
random
doubleblind
trial
adult
patient
mild
cap
day
outcom
clinic
success
pathogen
erad
radiolog
respons
durat
hospit
similar
group
wherea
advers
reaction
occur
frequent
among
patient
receiv
day
amoxicillin
convent
treatment
approach
intraven
therapi
continu
definit
clinic
cure
achiev
base
nonrandom
studi
patient
mild
moder
sever
cap
patient
hospit
cap
manag
safe
effici
earli
switch
iv
oral
medic
patient
sever
cap
earli
switch
oral
antibiot
treatment
also
seem
reduc
length
hospit
stay
approxim
day
treatment
associ
cost
without
advers
effect
treatment
outcom
prevent
prevent
cap
instanc
vaccin
may
well
reduc
antibiot
use
thu
resist
develop
regard
respiratori
infect
vaccin
avail
pneumococci
influenza
current
pneumococc
polysaccharid
vaccin
ppv
cover
preval
serotyp
pneumonia
recommend
western
countri
person
high
risk
develop
cap
howev
avail
data
support
recommend
far
consist
nonexperiment
retrospect
studi
suggest
ppv
effect
costsav
prevent
invas
pneumococc
diseas
howev
confound
indic
might
play
consider
role
studi
affect
valid
result
sever
clinic
studi
systemat
review
yield
conflict
result
regard
prevent
bacterem
pneumonia
even
highrisk
patient
previous
hospit
cap
therefor
real
valu
pneumococc
vaccin
strategi
term
effect
nonbacterem
pneumonia
cost
need
explor
prefer
random
control
trial
influenza
vaccin
recommend
patient
high
risk
influenza
complic
like
sever
viral
pneumonia
sever
secondari
bacteri
infect
patient
high
risk
complic
identifi
base
host
characterist
age
gender
comorbid
extern
factor
longterm
immunosuppress
drug
use
resid
close
commun
high
transmiss
rate
metaanalysi
vaccin
effect
prevent
hospit
prevent
death
highrisk
patient
addit
elderli
patient
younger
person
highrisk
medic
condit
might
also
benefit
annual
influenza
vaccin
data
clinic
effect
vaccin
reduc
postinfluenza
complic
among
highrisk
person
work
age
limit
indic
limit
benefit
vaccin
quantit
effect
antibiot
use
influenza
vaccin
unknown
tempt
argu
effect
influenza
vaccin
program
might
reduc
antibiot
use
cap
still
among
frequent
encount
infect
account
consider
antibiot
consumpt
strategi
fight
antibiot
resist
popul
level
includ
sever
basic
approach
treat
necessari
prescrib
antibiot
bacteri
infect
treat
caus
pathogen
reduc
durat
treatment
much
possibl
physician
care
cap
patient
balanc
principl
optim
treatment
individu
patient
frequent
includ
broadspectrum
antibiot
empir
therapi
especi
patient
sever
cap
clinic
featur
adequ
predict
caus
microorgan
establish
etiolog
diagnosi
mean
urinari
antigen
test
realtim
pcr
techinqu
may
enhanc
streamlin
therapi
therebi
reduc
antibiot
pressur
current
guidelin
advis
broad
spectrum
antibiot
either
combin
antibiot
plu
macrolid
monotherapi
fluoroquinolon
empir
treatment
sever
cap
yet
differ
definit
use
cap
sever
recommend
earli
broadspectrum
therapi
support
highlevel
evid
effect
recommend
resist
develop
clear
reason
concern
restrict
prudent
still
respons
use
antibiot
cap
could
possibl
achiev
improv
techniqu
establish
etiolog
diagnos
optim
empir
treatment
random
trial
optim
durat
therapi
implement
vaccin
strategi
howev
hypothes
remain
proven
